Skip to main navigation

Careers

About Us
Scientific Focus

Our Focus

Our Platform Technologies:
Turbo-ZM™ RMAs / ERSGs
Class 1 CF
Pipeline

Pipeline

Class 1 CF

RDEB/JEB

FAP & CRC
Scientific Documents
Investors

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials and Filings

Stock Information

Analyst Coverage

Investment Inquiries

Press Releases

Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investment Inquiries

Year

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

June 14, 2023

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

June 6, 2023

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

May 24, 2023

Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

May 15, 2023

Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013

May 2, 2023

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update

April 3, 2023

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

March 28, 2023

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 6, 2023

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed

February 27, 2023

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

January 25, 2023

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 20 of 20

TURBO-ZM is a trademark of Eloxx Pharmaceuticals, Inc..
©2023 Eloxx Pharmaceuticals, Inc.
Produced in the USA.
September 2023

Privacy Policy | Contact Us